James Davis, PharmD, BCOP
@thisisJamesD
Assistant professor & malignant hematology pharmacist @MUSCHollings #leukemia #lymphoma #myeloma opinions are my own
ID:1393178872808681479
14-05-2021 12:18:35
213 Tweets
372 Followers
176 Following
Frailty ≠ age in #MMsm …
Excellent work in Transplantation and Cellular Therapy Journal by James Davis, PharmD, BCOP Hamza Hashmi et al!
Safety and efficacy of eltrombopag in patients with post-CAR T cytopenias pubmed.ncbi.nlm.nih.gov/38044594/ by William Wesson Nausheen Ahmed MD Leyla Shune MD Hamza Hashmi James Davis, PharmD, BCOP #Cart #USMIRC USMIRC News #MedTwitter #MedEd OncoAlert #mmsm KU Cancer Center
Great Peer Exchange with an amazing group on myelofibrosis with James Davis, PharmD, BCOP Zahra M, PharmD, MBA, BCOP, FHOPA Victoria Nachar and Shawn Griffin
pharmacytimes.com/view/myelofibr…
Rockstar fellow Danai Dima presenting our multi-center #ASH23 abstract investigating #teclistamab outcomes in real-world patients. 👏🏼🤓👏🏼Hamza Hashmi Nausheen Ahmed MD Zahra M, PharmD, MBA, BCOP, FHOPA Al-Ola A Abdallah MD (USMIRC)
Don’t miss out oral presentation on the largest RWE of Teclistamab in #RRMM Dec 9th at #ASH23 by Danai Dima. More than 100 pts w median PFS & info on CRS, ICANS, infections, hypogam, 50% prior BCMA Faiz Anwer MD Larry Anderson,MD,PhD,FACP Gurbakhash Kaur James Davis, PharmD, BCOP Al-Ola A Abdallah MD (USMIRC)
ASH
Nivo-AVD >> BV-AVD age 60+ S1826 Andrew M. Evens, DO, MBA, MSc #ASH23 :
- 97 pts, 47% IPS 4+
- 1-yr PFS 93% N-AVD (vs 64% BV-AVD); 👀those curves!
- less sepsis/infx in N-AVD; more neuropathy in BV (49% Gr 2+!)
- 14% NRM with BV-AVD! (v 4% N-AVD)
New SOC for older cHL! #lymsm
ash.confex.com/ash/2023/webpr…
#epcoritamab vs #glofitamab battle of the bispecifics. hopefully the first of many collabs with Victoria Nachar 👏🤓😎 #lymsm #oncopharm tandfonline.com/doi/full/10.10…
#ASH23 Real-World Safety and Efficacy of Teclistamab for Rel/Ref Myeloma. N=102, >80% ineligible for MajesTEC-1, prior BCMA Rx: 55%. ORR: 64%, ORR with prior BCMA Rx: 57%, infections: 28%. 6-month PFS: 38% #mmsm Danai Dima Hamza Hashmi Al-Ola A Abdallah MD (USMIRC) ash.confex.com/ash/2023/webpr…
5 real-world teclistamab experiences (with n>50) to date.
Mohan: tinyurl.com/yz4shbtp
Dima: tinyurl.com/tw799trf
Midha: tinyurl.com/jvbde9t4
Asoori: tinyurl.com/bdz494vw
Riedhammer: tinyurl.com/yc8eu457
#mmsm
#ASH23
Johannes Waldschmidt Leo Rasche
Outstanding work by the team Danai Dima James Davis, PharmD, BCOP Hamza Hashmi #USMIRC Using Teclistimab in RW (55% were refractory to BDT): ORR was 64% for the entire cohort; ORR was 57%, 66% and 45% for patients who were BDT-refractory, penta-refractory, or had EMD, respectively Hira Shaikh…